Retina

The platform, developed by University College London and Heidelberg Engineering, demonstrated accuracy and precision in early tests

Researchers at the Korea Advanced Institute of Science and Technology demonstrated the next-generation strategy for sustainable synthesis

Cannabis has been shown to reduce microglial activity, expression of inflammatory cytokines and retinal neurotoxicity

Health Canada approves Aflivu, a biosimilar for retinal diseases, enhancing treatment options and affordability for Canadian patients.

Phil Lai, MD, chief medical officer of Perfuse Therapeutics, said the company's goal is to pioneer disease-modifying treatment that targets an underlying pathology of ischemia

The imaging innovation project is named after the company's co-founder Gerhard Zinser, PhD

In-orbit imaging drives innovation in terrestrial telemedicine, the NASA scientist explained

Investigators obtained data from genome‐wide association studies to examine the effects of instant coffee consumption

With fewer injections and sustained vision gains, the updated Eylea regimen offers new hope for patients with age-related macular degeneration and diabetic macular edema.

Christine A. Curcio, PhD, shares an update on histology and its critical role in advancing <3 μm optical coherence tomography interpretation

Preliminary analysis of FLIO data using artificial intelligence suggests potential novel biomarkers

High-resolution optical coherence tomography illuminates crucial biomarkers in age-related macular degeneration, Dr Sadda said

Prof Baljean Dhillon advocated for remote practices and provided advice for implementation at the International SPECTRALIS Symposium

Dinah Zur, MD, shares insights from her International SPECTRALIS Symposium lecture

Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS, presented two studies involving the EZ line at this year’s International SPECTRALIS Symposium

Ophthalmologists may be “at the forefront of a revolution in healthcare,” the nephrology professor said at this year’s International SPECTRALIS Symposium

The new technology will be crucial to imaging retinal function in the future, Prof Hüttmann predicted at the International SPECTRALIS Symposium

Prof Hogg presented a wide breadth of research at the International SPECTRALIS Symposium

Brazilian ANVISA has granted marketing authorisation for FYB201 (Ranivisio), a biosimilar to Lucentis.

Long-term benefits and vision preservation using an extended macular vision IOL

The therapy planning support tool has been trained on thousands of patient cases from more than 200 retina centres throughout Europe

Lysine, proline and arginine levels progressively increased from non-proliferative DR to proliferative DR stages

Vitamins B6, B9 and B12 were found to be neuroprotective against retinal ganglion cell death

The OCT platform offers deep imaging depth, rapid sweeping speed, extensive scan range, accurate results and multimodal imaging capabilities